logo
  

Valero Buys Corpus Christi Terminal Services Business For $465 Mln

Valero Energy Partners LP (VLP) on Wednesday said the board of its general partner has approved the Partnership's acquisition of the Corpus Christi Terminal Services Business from a subsidiary of Valero Energy Corp (VLO) for $465 million. The transaction is expected to close effective October 1.

The business to be acquired includes two terminals that support Valero Energy Corp's Corpus Christi East and West refineries. The assets consist of 134 tanks with 10.1 million barrels of storage capacity for crude oil, intermediates, and refined petroleum products.

Valero Energy Partners expects to finance the acquisition with $395 million in borrowings under a subordinated loan agreement with Valero Energy Corp, as well as the issuance of additional common units and general partner units to Valero subsidiaries, valued collectively at about $70 million. The newly issued units will be allocated in a proportion allowing the general partner to maintain its 2 percent general partner interest.

Upon closing, Valero Energy Partners plans to enter into a 10-year terminaling agreement with a subsidiary of Valero Energy Corp. The business to be acquired is expected to contribute about $50 million of EBITDA in its first full year of operation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT